Finding genetic targets in ovarian tumors
Official title: Identification of Genetic Targets in Gynecological Tumors Via a Triple in Silico Ex-vivo / in Vivo Approach
Run by Azienda USL Reggio Emilia - IRCCS · NCT07169396 · Data updated 2026-11-12
This project will test whether specific genes and hormone-related pathways differ between tumor and normal ovarian tissue in adult women with epithelial ovarian cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 180 (estimated) |
| Sponsor | Azienda USL Reggio Emilia - IRCCS Government |
| Locations | 1 site (Reggio Emilia) |
| Status | Recruiting |
| Started | November 17, 2021 |
| Main results expected | November 17, 2021 |
| Study ends | November 2027 |
| Registry record updated | July 24, 2026 |
| Trial ID | NCT07169396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women (age ≥18) with histologically confirmed epithelial ovarian cancer (including high-grade serous, endometrioid, mucinous, clear cell, or mesonephric-like subtypes) or patients providing control ovarian tissue during benign surgery are eligible, with prospective cases requiring informed consent.
✕Probably not a fit
Patients with low-grade or non-epithelial ovarian tumors or those without sufficient clinical or pathological data are unlikely to be included or benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This monocentric observational project at Azienda USL IRCCS Reggio Emilia combines computational, tissue-based, and cell-line experiments to search for genetic drivers and biomarkers in ovarian cancer. Investigators will mine public transcriptomic datasets, measure mRNA and protein levels in fresh-frozen and FFPE patient samples, and perform functional overexpression and silencing experiments in ovarian cancer cell lines. The work includes both prospective patients who provide informed consent and retrospective samples obtained under ethical waiver, with control tissue from benign surgeries. Results aim to highlight genes or pathways, including gonadotropin and membrane estrogen receptor signaling, that differentiate tumors from normal ovarian epithelium.
Why it matters
Potential benefit: If successful, this work could identify diagnostic markers or new therapeutic targets that help guide future treatments for epithelial ovarian cancer.
How similar studies have gone: Related transcriptomic and functional studies have previously identified candidate biomarkers in ovarian cancer, but targeting gonadotropin-related signaling remains largely exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult women ≥18 years old * Histologically confirmed diagnosis of epithelial ovarian cancer (including high- grade serous, endometrioid, mucinous, clear cell, or mesonephric-like histotypes) * Signed informed consent (for prospective cases) or ethically approved waiver (for retrospective samples) Exclusion Criteria: * Refusal to sign informed consent * Diagnosis of low-grade or non-epithelial ovarian tumors * Patients whose clinical or pathological data are unavailable or insufficient for study inclusion
Where it's running
-
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy Recruiting
Study contacts
- Study coordinator: Beatrice Melli, MD
- Email: beatrice.melli@ausl.re.it
- Phone: 0522-29577
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.